Lyrica (Pregabalin) molecular model

Lyrica (Pregabalin) molecular model

C024/9858 Rights Managed

Request low-res file

530 pixels on longest edge, unwatermarked

Request/Download high-res file

Uncompressed file size: 9.8MB

Downloadable file size: 465.8KB

Price image Pricing

Please login to use the price calculator


Credit: SCIMAT/SCIENCE PHOTO LIBRARY

Caption: Lyrica (Pregabalin) ((S)-3-(aminomethyl)-5-methylhexanoic acid) was approved in 2007 by the U.S. Food and Drug Administration for the treatment of fibromyalgia. Until then, Pregabalin was used to treat diabetic peripheral neuropathy, post-herpetic neuralgia, and as an additional therapy for adults with partial onset seizures. Lyrica's mode of action is not known. It is thought to work by binding to calcium channels found on nerve cells in the brain and spinal cord. This reduces the release of various neurotransmitters from these nerve cells. The effectiveness of Lyrica (300 or 450 mg/day) for treating fibromyalgia was established by two clinical trials involving 1,800 people. Lower doses (e.g. 50 mg as shown) have been used to treat severe neuropathic

Release details: Model release not required. Property release not required.

Keywords: 50 mg, adverse side effects, calcium channels, capsules, chemical, chemistry, diabetic peripheral neuropathy, fibromyalgia, lyrica, medicine, modelling, models, molecular, nerve cells, neuropathic pain, neurotransmitters, pills, post-herpetic neuralgia, pregabalin, seizures, structure, white background

Licence fees: A licence fee will be charged for any media (low or high resolution) used in your project.